BOMP

This combination chemotherapy regimen is known by the acronym BOMP, which stands for Bleomycin, vincristine (Oncovin), Mitomycin C, and cisPlatin[1][3]. It has been used in the treatment of various advanced squamous cell carcinomas, particularly for vulvar and cervical cancers. ## Composition and Administration The BOMP regimen typically consists of: - Bleomycin: An antineoplastic antibiotic that inhibits DNA synthesis - Vincristine: A vinca alkaloid that disrupts microtubule formation - Mitomycin C: An alkylating agent that cross-links DNA - Cisplatin: A platinum-based compound that forms DNA adducts In some studies, a modified version called CLD-BOMP (Consecutive Low-Dose BOMP) has been used with the following dosing schedule: - Bleomycin: 5 mg infused continuously days 1 through 7 - Vincristine: 0.7 mg/m² bolus on day 7 - Mitomycin: 7 mg/m² bolus on day 7 - Cisplatin: 10 mg/m² infused over 4 hours days 1 through 7[3] This regimen is typically repeated at 3-week intervals. ## Clinical Applications The BOMP combination has demonstrated efficacy in: 1. Advanced squamous cell carcinoma of the vulva, where it has shown complete response in some inoperable cases[1] 2. Recurrent cervical carcinoma, with significant response rates (76% overall response rate, including 28% complete responses)[3] ## Efficacy and Outcomes In a study of 90 patients with recurrent cervical carcinoma, the CLD-BOMP regimen showed: - 76% objective response rate - 28% complete responses - 48% partial responses - Median survival of 24.3 months for all patients[3] ## Toxicity Profile The CLD-BOMP regimen has shown a favorable toxicity profile compared to standard cisplatin-containing regimens: - Reduced nausea and vomiting - Minimal nephrotoxicity - Limited pulmonary toxicity - Generally tolerable with few severe side effects[1][3] The reduced toxicity is attributed to the consecutive low-dose administration of cisplatin and appropriate dosing schedule of bleomycin, allowing the regimen to be administered at projected dose intensities[3]. In some studies, treatment-related deaths have been reported, though the regimen appears to have a response rate similar to other cisplatin-containing combinations[2]. ## Variants A similar combination called CABO (Cisplatin, methotrexate, Bleomycin, and vincristine/Oncovin) has been assessed in advanced epidermoid head and neck cancer[5]. In some cases, carboplatin has been substituted for cisplatin in a variant called BOM-carboplatin[6].

Other names

bleomycin + cisplatin + mitomycin + vincristineBleomycin, vincristine (Oncovin), Mitomycin C, and cisPlatin